Author: igdadmin

December 27, 2023

US FDA approval based on NEURO-TTRansform Phase III results showing WAINUA demonstrated consistent and sustained benefit improving neuropathy impairment and…

October 12, 2023

Be sure to catch up on the latest happenings in our fall newsletter here!

July 17, 2023

PALO ALTO, Calif., July 17, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), is a commercial-stage…

July 13, 2023

Be sure to catch up on the latest happenings in our summer newsletter here!

May 25, 2023

By Shelley Wood  MAY 23, 2023 PRAGUE, Czechia—A phase I, randomized, double-blind trial of an intravenous antibody in transthyretin amyloid (ATTR)…

May 3, 2023

Oxford, UK, April 26th, 2023 — Ultromics, a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been…

April 24, 2023

WILMINGTON, Del.--(BUSINESS WIRE)--Detailed results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca…

April 19, 2023

Be sure to catch up on the latest happenings in our spring newsletter here!

February 2, 2023

Be sure to catch up on the latest happenings in our winter newsletter here!

November 30, 2022

November 5, 2022 CAMBRIDGE, Mass., Nov. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing…